BenchSci
Toronto, Canada· Est.
BenchSci’s neuro‑symbolic AI platform unlocks disease biology to speed drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
BenchSci’s neuro‑symbolic AI platform unlocks disease biology to speed drug discovery.
OncologyImmunologyNeuroscienceCardiovascularMetabolic
Technology Platform
ASCEND is a neuro‑symbolic AI platform built on the Biological Evidence Knowledge Graph, which integrates curated scientific literature, multi‑omics, and clinical data with multimodal deep‑learning models and human‑in‑the‑loop validation.
Opportunities
Scaling ASCEND across more therapeutic areas, deepening integration with internal pharma data, and licensing the BEKG to AI model developers could drive significant revenue growth.
Risk Factors
Reliance on proprietary data licenses, maintaining curation quality at scale, and competition from other AI drug‑discovery platforms pose key risks.
Competitive Landscape
BenchSci competes with Insilico Medicine, BenevolentAI, Exscientia and and larger LLM‑based platforms, differentiating itself through an evidence‑backed knowledge graph and neuro‑symbolic reasoning that reduces hallucinations.